HDAC inhibition may combat resistance to anti-PD-1 therapy in patients with melanoma
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical responses in patients with melanoma that had progressed on prior anti-PD-1 ...
Apr 1, 2019